NOTICE: Investors in NRx Pharmaceuticals, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – NRXP; NRXPW – QNT Press Release

[ad_1]

Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NRx Pharmaceuticals, Inc. (NASDAQ:NRXPNRXPW)) securities between June 1, 2021 and November 4, 2021, both dates inclusive (the “Class Period”) have until March 21, 2022 to seek appointment as lead plaintiff in Dal Bosco v. NRx Pharmaceuticals, Inc.No. 22-cv-00066 (D. Del.). Commenced on January 18, 2022 and pending before Judge Maryellen Noreika, the NRx Pharma class action lawsuit charges NRx as well as certain of its top executives with violations of the Securities Exchange Act of 1934.

If you suffered significant losses and wish to serve as lead plaintiff of the NRx Pharma class action lawsuit, please provide your information by clicking here. You can also contact attorney JC Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com. Lead plaintiff motions for the NRx Pharma class action lawsuit must be filed with the court no later than March 21, 2022.

CASE ALLEGATIONS: NRx is a clinical-stage small molecule pharmaceutical company that develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. NRx’s products include, among others, ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure. In June 2021, NRx announced that it filed an application with the US Food and Drug Administration …

Full story available on Benzinga.com

[ad_2]

Source link

Recommended For You

About the Author: News Center